Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux, a world leader in the field of in vitro diagnostics, are teaming up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

The companies are jointly exploring selected opportunities to advance patient care by providing access to nanopore-based clinical research and in vitro diagnostic (IVD) solutions.
Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. The resulting signal is decoded to provide the specific DNA or RNA sequence. The unique real-time, scalable features of this technology make it ideal for the rapid and cost-effective characterization of pathogens in clinical samples.
Offering rapid and accurate identification of microbial pathogens and associated antimicrobial resistance, Oxford Nanopore is uniquely positioned to deliver nanopore-based sequencing solutions that provide comprehensive results and reduce time to results for infectious diseases research and diagnostic applications.
Initial areas of collaboration will include a test for determining antibiotic resistance of tuberculosis; an assay to identify pathogens in normally sterile clinical samples; and validating Oxford Nanopore’s sequencing platform with BIOMÉRIEUX EPISEQ CS application for rapid infection outbreak monitoring in patient-care settings.